Viral Conjunctivitis Pipeline Drugs Market
Viral Conjunctivitis Pipeline Drugs Market (Drug Type - FST-100 and APD-209) - Global Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023
Press Release :
Viral conjunctivitis therapeutics is undergoing a transitional phase. Currently, there is no drug available for the treatment of viral conjunctivitis. However, the presence of a robust pipeline indicates towards a thriving future. The global market for viral conjunctivitis pipeline drugs is likely to exhibit a thumping CAGR of 69.60% between 2020 and 2023 and reach an opportunity worth US$462.4 mn by the end of the forecast period.
The increasing investments from ophthalmic drug manufacturers for the development of efficient treatment for viral conjunctivitis, coupled with the increasing awareness among people and augmenting expenditure on healthcare, are accelerating the growth rate of this market significantly.
On the other hand, lower diagnosis rate of viral conjunctivitis is decreasing the patient pool for the treatment, causing major hindrance in the market’s growth.
Pipeline Drugs in U.S. Gain Momentum from Promising Results of Ongoing Clinical Trials
The U.K., the U.S., Germany, Australia, Japan, and Brazil are the key regional markets for viral conjunctivitis pipeline drugs. Considering the ongoing clinical trials, the U.S. is likely to occupy the leading position among these in the coming years. The major factors driving the growth in this market are promising results of the ongoing clinical trials, the increasing awareness regarding eye care among patients and medical professionals, the high cost of the drugs, and the availability of viral conjunctivitis diagnostic tests.
The U.S. market for viral conjunctivitis pipeline drugs is projected to report a CAGR of 46.50% during the period from 2020 to 2023.
APD-209 to Exceed FST-100 by 2023
APD-209 and FST-100 are the main viral conjunctivitis drugs in the pipeline. Among the two, FST-100 is projected to hold the largest share in the market by 2020. Foresight Biotherapeutics Inc. initiated the development of FST-100; however, the company was acquired by Shire Plc. in the midway. In May 2014, the drug completed its phase II clinical trial successfully and is expected to enter the phase III of clinical trials in 2016.
Presently, the APD-209 is witnessing moderate rise; however, in the coming years, it will report a higher demand than FST-100. The drug, being developed by Adenovir Pharma AB, is in its second phase of clinical trial. It is likely to enter the third phase by mid-2016.
The market for FST-100 is projected to rise at a CAGR of 27.40% between 2020 and 2023 while the APD-209 market is likely to report a CAGR of 55.0% during the same period.
Leading Players Focus on Research Activities Thanks to Escalating Demand for Targeted Drugs for Viral Conjunctivitis
On the forefront of the global viral conjunctivitis pipeline drugs market are Panoptes Pharma GES.M.B.H., Shire Plc., Allergan Plc, Novartis AG, NovaBay Pharmaceuticals Inc., Adenovir Pharma AB, NicOx S.A., and NanoViricides Inc. As the demand for targeted drugs for viral conjunctivitis is rising, leading enterprises are focusing aggressively on research activities for the development of efficient treatments as well as diagnostic tests for viral conjunctivitis. New entrants in this market are recommended to enhance their distribution networks through strategic partnerships and alliances with local distributors.
Global Viral Conjunctivitis Pipeline Drugs Market: Overview
Viral conjunctivitis, or “pink-eye”, is a highly contagious infection of the eye, wherein irritation, redness, watery discharge, and photophobia or light sensitivity are common symptoms. Currently, there is no approved treatment for this disease. Therefore, the use of viral conjunctivitis drugs is increasingly becoming mainstream, opening up a broad avenue for these medications. The market for viral conjunctivitis drugs will show an exceptional CAGR of 69.60% during the forecast period 2020-2023, when the projected revenue will reach US$462.4 mn by 2023.
The report furnishes a combined analysis of primary and secondary research gathered from multiple sources, along with the projected market size for every drug that will be introduced in the market by 2023. The CAGR for every segment of the market is revealed. Competition between various existing and viral conjunctivitis drugs, future trends, demographics, epidemiological analysis, regulatory policies, and the overall market landscape have been described extensively. The key catalysts and challenges faced by the global viral conjunctivitis drugs market have been analyzed in the overview section.
The market forecast for the leading countries covers the period from the expected launch up to 2023, together with their respective CAGRs. The report includes significant factors such as the awaited launch date, the number of patients suffering from viral conjunctivitis, and product innovation in each country. The major companies have been profiled in the report, with emphasis on their recent developments, financial overview, business tactics, and product portfolio.
Global Viral Conjunctivitis Pipeline Drugs Market: Trends and Opportunities
The global viral conjunctivitis drugs market can be broadly categorized according to region and type of drug. FST-100 and APD-209 are the chief drugs in the global viral conjunctivitis drug market. Of these, FST-100 will be more prominent by 2020, suggests TMR. The development of FST-100 was undertaken by a leading drug development company, Foresight Biotherapeutics Inc., which was later acquired by Shire Plc. when the drug was still under development. If approved, the drug will be the premier medication for the treatment of viral and bacterial eye infections, thus promising exhaustive opportunities in the global viral conjunctivitis drugs market.
However, APD-209, though rising in demand at a gradual rate, is likely to witness a higher demand than FST-100. Adenovir Pharma AB has been developing the drug, which is presently in its second stage.
Global Viral Conjunctivitis Pipeline Drugs Market: Regional Outlook
According to regional segmentation, the viral conjunctivitis drugs markets in the U.K., Germany, the U.S., Japan, Brazil, and Australia are evaluated. Owing to the current clinical trials in the U.S., the country is expected to lead the other regions over the coming years. Extensive R&D activities, growing awareness about eye-related diseases, bright prospects of current clinical trials, and the presence of viral conjunctivitis diagnostic tests are few of the many catalysts promoting the U.S. viral conjunctivitis drug market. A favorable CAGR of 46.50% is expected during the forecast period in this regional segment.
Companies Mentioned in the Report
As the demand for viral conjunctivitis drugs is multiplying, major companies are vigorously engaging in research activities so as to bring forth fruitful treatments and diagnostic tests for viral conjunctivitis. The key market players mentioned in the report are Allergan Plc, Panoptes Pharma GES.M.B.H., NovaBay Pharmaceuticals Inc., Shire Plc., NicOx S.A., NanoViricides Inc., and Adenovir Pharma AB.
The viral conjunctivitis drugs market has been segmented as follows:
Viral Conjunctivitis Pipeline Drugs Market, by Drug
Viral Conjunctivitis Pipeline Drugs Market, by Country
Major regions analyzed under this research report are:
- North America
- Asia Pacific
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments